A Symmetry Breaking in Design and Production of Enantiomeric Drugs
A special issue of Symmetry (ISSN 2073-8994). This special issue belongs to the section "Chemistry: Symmetry/Asymmetry".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 2597
Special Issue Editor
Interests: asymmetric synthesis; synthesis of bidentant chiral ligands; fine organic synthesis; cross-metathesis reactions; CH activation; computer simulation of organic processes; some aspects of supramolecular chemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Chirality, as a fundamental property of 3D objects (including many molecules and ions) to be non-superimposable on their mirror images, is imprinted on such basic building blocks of life as amino acids and sugars; it is further reflected by the chirality of more complex biochemical objects such as DNA, and finally, by the chirality of entire bodies. Each chiral compound exists as one of two possible isomeric molecules (or as a mixture of those two stereoisomers) that are related to one another as an object (e.g., right hand) and its mirror image (left hand). The biological properties of such optical isomers are often different: One of them could be a drug (e.g., (R)-(+)-thalidomide) but another a poison (e.g., (S)-(-)-thalidomide). Today, approximately 50% of marketed drugs are chiral. According to the U.S. Food and Drug Administration (FDA) policy, published in 1992, regarding single optical isomers (enantiomers), although both mixture and single optical isomeric drugs will continue to be developed, a higher proportion of single optical isomers are being submitted for new drug approval. The fundamental research enhances the understanding of the fine stereochemical mechanism of chemical processes that should help to design more efficient, cheaper, and more environmentally beneficial industrial methods of enantiomeric drug production. In this issue, we primarily focus on modern practical methods of symmetry breaking, which are of interest to the pharmaceutical industry, while manuscripts dedicated to the analysis of current status of the industry and the market of chiral drugs will also be considered for publication.
Prof. Dr. Oleh M. Demchuk
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Symmetry is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Chiral drugs
- Enantiomeric drug
- Symmetry breaking
- Origin of asymmetric induction
- Pharmaceutical industry
- Sereoselective industrial methods
- Market of chiral drugs
